• Milestone Payments Triggered following EC Approval

News & Views

Milestone Payments Triggered following EC Approval

UK pharmaceutical company Diurnal Group specialising in chronic endocrine (hormonal) diseases, has announced a payment of $1.0 million of a possible $1.25 from its China partner Citrine Medicine, following the recent European Commission’s (EC) approval for Efmody® (hydrocortisone modified-release hard capsules) and the attainment by Citrine of certain development milestones in China for Alkindi® (hydrocortisone granules in capsules for opening). This followed the company’s extension of its exclusive license agreement with Citrine covering Efmody® development in May 2021 to cover Efmody® and subsequently triggered the receiving the upfront payment.

Citrine, a therapeutics platform company focused on the Greater China market, has licensed the registration and commercialisation rights for the two products in China, Hong Kong, Taiwan and Macau and continues to plan for a New Drug Application (NDA) submission to the National Medical Products Administration in 2021 for Alkindi®.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

Further information online


Digital Edition

Lab Asia 31.6 Dec 2024

December 2024

Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...

View all digital editions

Events

Turkchem

Nov 27 2024 Istanbul, Turkey

Smart Factory Expo 2025

Jan 22 2025 Tokyo, Japan

Instrumentation Live

Jan 22 2025 Birmingham, UK

SLAS 2025

Jan 25 2025 San Diego, CA, USA

Arab Health

Jan 27 2025 Dubai, UAE

View all events